Vol 13, No 4 (April 30, 2024): Translational Andrology and Urology

Original Article

Real-world clinical effectiveness of nonsurgical treatments for female with POP-Q stage II cystocele: a retrospective analysis of therapeutic efficacy
Cuiping Jin, Hongliang Yan, Yumin Shang, Chaoqun Dong, Pengfei Li, Yang Tang, Fuling Ma, Yuanjie Niu
Survival nomogram and risk classification system for patients with adrenocortical carcinoma: a study based on the SEER database and external validation in China
Zhizhou Li, Maoyu Wang, Wei Gang, Yidie Ying, Ziwei Wang, Qing Chen, Xufeng Yu, Wei He, Shuxiong Zeng, Zhensheng Zhang, Chuanliang Xu, Huiqing Wang
Identification of a lactate metabolism-related lncRNAs signature for predicting the prognosis in patients with kidney renal clear cell carcinoma
Tianzi Xu, Yixin Liu, Biao Ning, Min Luo, Yongchang Wei
Porous Se@SiO2 nanocomposites play a potential inhibition role in hyperoxaluria associated kidney stone by exerting antioxidant effects
Chen Ye, Lin Zhao, Jiaying Miao, Chengyu Gong, Yuangui Chen, Shengfei Qin, Nicholas N. Tadros, Stefan Aufderklamm, Wenli Jiang, Guoying Deng, Shaoxiong Ming
Nitro-oleic acid (NO2-OA) ameliorates erectile dysfunction in a rat model of diabetes mellitus via modulation of fibrosis, inflammation and autophagy
Changbo Zhao, Weibo Chen, Fangxin Gong, Wenzhen Wang, Cuiqin Fan, Ye Li, Tian Lan, Wenjing Wang, Mingzhen Yuan
Differential effects of obesity on perioperative outcomes in renal cell carcinoma patients based on race and ethnicity and neighborhood-level socioeconomic status
Waheed Asif, Irasema C. Paster, Kathryn R. Pulling, Kyle Garcia, Patrick Wightman, Alejandro Cruz, Christopher Combates, Eric C. Kauffman, Francine C. Gachupin, Benjamin R. Lee, Juan Chipollini, Ken Batai

Editorial Commentary

European association of urology biochemical recurrence risk stratification in the context of post-prostatectomy salvage therapy
Timothy A. Lin, Daniel Y. Song
Metabolic enzymes moonlighting to drive enzalutamide resistance in prostate cancer
Maria Rusan, Simone Weiss, Karina Dalsgaard Sørensen
Effectiveness of switch therapy from tyrosine kinase inhibitors to immune checkpoint inhibitors: the need for biomarkers to establish treatment strategies in patients with metastatic renal cell carcinoma
Yoshihiko Tasaki, Shuzo Hamamoto, Yoko Furukawa-Hibi, Takahiro Yasui
Refining the subgroup analyses and optimal patient population in the JAVELIN Bladder 100 trial
Jeanny B. Aragon-Ching
Chemoablation with UGN-102 in intermediate-risk non-muscle invasive bladder cancer, are we there yet?
Daniel A. González-Padilla, José Daniel Subiela, Felipe Villacampa-Aubá
Management of small renal mass: unmet needs and quest for high quality evidence
Leslie Claire Licari, Eugenio Bologna, Riccardo Autorino
Ablative therapy with UGN-102 for low-grade intermediate risk non-muscle-invasive bladder cancer: ready for primetime?
Benjamin Lichtbroun, Saum Ghodoussipour, Vignesh T. Packiam
What is the key factor determining effectiveness of radiotherapy for high-risk prostate cancer: a hidden message from RTOG 0521
Keisei Okamoto
A critical evaluation of Optilume® BPH as a novel minimally invasive surgical treatment for the management of lower urinary tract symptoms in men
David C. Chen, Alice Thomson, Siyu Huang, Declan G. Murphy, Damien Bolton, Nathan Lawrentschuk, Marlon L. Perera